Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety

Bibliography

• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).
   Google Scholar
• ▪ Evidence-based report outlining the recommendations for cholesterol management emphasizing strategies to prevent coronary heart disease (CHD). Lowering of LDL-C is recognized as the key goal of lipid-modifying therapy. Specific CHD risk categories and high-risk patient populations are identified to guide appropriate clinical intervention.
   Google Scholar
• Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. National Health Statistics Reports. National Center for Health Statistics, MD, USA (2009).
   Google Scholar
• Mathieu P, Pibarot P, Despres JP: Metabolic syndrome: the danger signal in atherosclerosis.Vasc. Health Risk Manag. 2(3), 285–302 (2006).
   Google Scholar
• Wong ND: Metabolic syndrome: cardiovascular risk assessment and management. Am. J. Cardiovasc. Drugs 7(4), 259–272 (2007).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
   Google Scholar
• Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ: Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin. 23(3), 553–563 (2007).
   Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al.: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(10 Suppl.), 1K–34K (2008).
   Google Scholar
• Ansell BJ: Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr. Atheroscler. Rep. 7(1), 29–33 (2005).
   Google Scholar
• Fievet C, Staels B: Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr. Opin. Lipidol. 20(6), 505–511 (2009).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227–239 (2004).
   Google Scholar
• ▪▪ Update of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines based on the completion of key statin therapy trials. New recommendations include optional LDL-C goals for patients at very high risk and combination therapy with a statin plus a fibrate or niacin for patients with high triglycerides and low HDL-C.
   Google Scholar
• McKenney JM: Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol. 96(4A), 60E–66E (2005).
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N. Engl. J. Med. 352(14), 1425–1435 (2005).
   Google Scholar
• Zocor®, prescribing information. Merck & Co., Inc., NJ, USA (2008).
   Google Scholar
• Farnier M: Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am. J. Cardiovasc. Drugs 3(3), 169–178 (2003).
   Google Scholar
• Tenenbaum A, Fisman EZ: Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc. Diabetol. 3, 10 (2004).
   Google Scholar
• Tenenbaum A, Fisman EZ, Motro M, Adler Y: Atherogenic dyslipidemia in metabolic syndrome and Type 2 diabetes: therapeutic options beyond statins.Cardiovasc. Diabetol. 5, 20 (2006).
   Google Scholar
• Tenenbaum A, Fisman EZ, Motro M, Adler Y: Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45, 127–153 (2008).
   Google Scholar
• Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-HDL Cholesterol: The importance of non-HDL cholesterol reporting in lipid management. J. Clin. Lipid. 2, 267–273 (2008).
   Google Scholar
• ▪ Overview of evidence supporting the NCEP ATP III, American Diabetes Association/American College of Cardiology (ADA/ACC) recommendations for non-HDL-C as a key secondary target of lipid management in patients with CHD risk after LDL-C.
   Google Scholar
• Robinson JG, Wang S, Smith BJ, Jacobson TA: Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.J. Am. Coll. Cardiol. 53(4), 316–322 (2009).
   Google Scholar
• ▪ To evaluate the effect of non-HDL-C reduction on cardiovascular outcomes (i.e., relative risk of nonfatal myocardial infarction and CHD death), the authors performed a meta-analysis of randomized placebo- or active-controlled clinical trials that reported at least one total cholesterol and HDL-C or non-HDL-C measurement after baseline. Findings support non-HDL-C as an important therapeutic target in accordance with NCEP ATP III and ADA/ACC recommendations.
   Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 25(7), 1198–1202 (2002).
   Google Scholar
• Goldberg AC, Bays HE, Ballantyne CM et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am. J. Cardiol. 103(4), 515–522 (2009).
   Google Scholar
• Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).Am. J. Cardiol. 95(4), 462–468 (2005).
   Google Scholar
• Mohiuddin SM, Pepine CJ, Kelly MT et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a Phase 3, randomized, controlled study. Am. Heart J. 157(1), 195–203 (2009).
   Google Scholar
• Vega GL, Ma PT, Cater NB et al.: Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol. 91(8), 956–960 (2003).
   Google Scholar
• Trilipix®, prescribing information. Abbott Laboratories, IL, USA (2008).
   Google Scholar
• Fruchart JC: Peroxisome proliferator-activated receptor-a activation and high-density lipoprotein metabolism. Am. J. Cardiol. 88(12A), 24N–29N (2001).
   Google Scholar
• Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. 4, 14 (2005).
   Google Scholar
• Shah A, Rader DJ, Millar JS: The effect of PPAR-a agonism on apolipoprotein metabolism in humans. Atherosclerosis 210(1), 35–40 (2009).
   Google Scholar
• Abourbih S, Filion KB, Joseph L et al.: Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122(10), 962 E1–E8 (2009).
   Google Scholar
• Crestor®, prescribing information. AstraZeneca, DE, USA (2010).
   Google Scholar
• McKenney JM: Efficacy and safety of rosuvastatin in treatment of dyslipidemia.Am. J. Health. Syst. Pharm. 62(10), 1033–1047 (2005).
   Google Scholar
• Jones PH, Davidson MH, Stein EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am. J. Cardiol. 92(2), 152–160 (2003).
   Google Scholar
• ▪ This short-term randomized, open-label Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial was the first to compare the efficacy of rosuvastatin with atorvastatin, simvastatin and pravastatin. Over a range of doses, rosuvastatin was significantly more effective in reducing LDL-C compared with approved doses of the other statins.
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N. Engl. J. Med. 359(21), 2195–2207 (2008).
   Google Scholar
• Filippatos T, Milionis HJ: Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin. Investig. Drugs 17(10), 1599–1614 (2008).
   Google Scholar
• Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34(2), 155–162 (1998).
   Google Scholar
• Zhu T, Awni WM, Hosmane B et al.: ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J. Clin. Pharmacol. 49(1), 63–71 (2009).
   Google Scholar
• ▪ Pharmacokinetic study in healthy volunteers presenting the finding that when rosuvastatin and fenofibric acid (FA) are coadministered there is no clinically significant drug–drug interaction, supporting the clinical development of this combination therapy.
   Google Scholar
• McKenney JM: An assessment of statin safety. Am. J. Manag. Care 12(11 Suppl.), S310–S317 (2006).
   Google Scholar
• Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann. Intern. Med. 150(12), 858–868 (2009).
   Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS: Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 10(1), 11–28 (2010).
   Google Scholar
• Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.Cardiology 107(4), 433–443 (2007).
   Google Scholar
• ▪ Overview of rosuvastatin Phase II–IV clinical program with regard to safety and tolerability data from a broad range of patients with dyslipidemia. The rosuvastatin safety profile was similar to those of comparator statins, with very low incidences of treatment-related myopathy and rhabdomyolysis.
   Google Scholar
• Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69(5), 340–345 (2001).
   Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75(5), 455–463 (2004).
   Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73(6), 538–544 (2003).
   Google Scholar
• Jacobson TA: Myopathy with statin-fibrate combination therapy: clinical considerations.Nat. Rev. Endocrinol. 5(9), 507–518 (2009).
   Google Scholar
• ▪ Comprehensive overview of statin and fibrate pharmacokinetic properties, discussion of factors that can contribute to adverse drug–drug interactions and recommendations for optimizing combination therapy to minimize these interactions and the subsequent risk of muscle-related toxicities.
   Google Scholar
• Alsheikh-Ali AA, Kuvin JT, Karas RH: Risk of adverse events with fibrates. Am. J. Cardiol. 94(7), 935–938 (2004).
   Google Scholar
• Davidson MH: Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf. 5(1), 145–156 (2006).
   Google Scholar
• Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95(1), 120–122 (2005).
   Google Scholar
• Martin PD, Dane AL, Schneck DW, Warwick MJ: An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Ther. 25(2), 459–471 (2003).
   Google Scholar
• Jones PH, Davidson MH, Kashyap ML et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a Phase 3 study. Atherosclerosis 204(1), 208–215 (2009).
   Google Scholar
• ▪ Key clinical trial demonstrating the efficacy and safety of rosuvastatin 10 and 20 mg in combination with FA in patients with mixed dyslipidemia after 12 weeks of treatment.
   Google Scholar
• Roth EM, Rosenson RS, Carlson DM et al.: A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. J. Am. Coll. Cardiol. 53(Suppl. A), A208 (2009).
   Google Scholar
• ▪▪ Abstract reporting 12-week efficacy results from a key clinical trial of a low-dose rosuvastatin (5 mg) in combination with FA in patients with mixed dyslipidemia. Final safety and efficacy data are forthcoming.
   Google Scholar
• Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K: Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. 64(2), 137–151 (2004).
   Google Scholar
• Elisaf M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18(5), 269–276 (2002).
   Google Scholar
• Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L: Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92(7), 794–797 (2003).
   Google Scholar
• Fazio S, Linton MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6(2), 148–157 (2004).
   Google Scholar
• Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW: Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30(8), 1945–1951 (2007).
   Google Scholar
• Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres JP: A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162(2), 363–371 (2002).
   Google Scholar
• Bays HE, Jones PH, Mohiuddin SM et al.: Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J. Clin. Lipid. 2, 426–435 (2008).
   Google Scholar
• ▪▪ Key clinical trial demonstrating the long-term (year 1) safety and sustained efficacy of rosuvastatin in combination with FA in patients with mixed dyslipidemia. Patients who completed the corresponding 12-week controlled trial [49] received rosuvastatin 20 mg plus FA for up to 52 weeks; simvastatin 40 mg/FA and atorvastatin 40 mg/FA combinations were also evaluated.
   Google Scholar
• Kipnes MS, Roth EM, Rhyne JM et al.: Year two assessment of fenofibric acid and moderate-dose statin combination. Clin. Drug Invest. 30(1), 51–61 (2010).
   Google Scholar
• ▪▪ Key clinical trial demonstrating the long-term (year 2) safety and sustained efficacy of rosuvastatin in combination with FA in patients with mixed dyslipidemia. Patients who completed the year 1 extension trial were enrolled [57].
   Google Scholar
• Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
   Google Scholar
• Scott R, O’Brien R, Fulcher G et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.Diabetes Care 32(3), 493–498 (2009).
   Google Scholar
• ▪ This post hoc analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study evaluated the prevalence of metabolic syndrome among patients with Type 2 diabetes and the risk of cardiovascular events over 5 years. Treatment with fenofibrate was associated with a significant reduction in the incidence of major cardiovascular events in patients with hypertryglyceridemia and low HDL-C.
   Google Scholar
• Roth EM, McKenney JM, Kelly MT et al.: Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia – a randomized study.Am. J. Cardiovasc. Drugs, 10(3), 175–186 (2010).
   Google Scholar
• ▪▪ Key clinical trial demonstrating the efficacy and safety of a fixed-dose combination of rosuvastatin 5, 10 or 20 mg and FA in patients with hypertriglyceridemia and high LDL-C compared with simvastatin monotherapy.
   Google Scholar
• Roth EM, Rosenson RS, Carlson DM et al.: A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. Presented at: 58th Annual Scientific Session of the American College of Cardiology. Orlando, FL, USA, 29–31 March 2009.
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al.: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563–1574 (2010).
   Google Scholar
• ▪▪ Although this Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid study found that combination therapy with simvastatin and a fibrate did not significantly improve cardiovascular outcomes in the overall population of patients with Type 2 diabetes, the relative risk of cardiovascular events was reduced compared with placebo in a subgroup of patients with high triglycerides and low HDL-C.
   Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165(10), 1154–1160 (2005).
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341(6), 410–418 (1999).
   Google Scholar
• Taskinen MR, Sullivan DR, Ehnholm C et al.: Relationships of HDL cholesterol, apoAI, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arterioscler. Thromb. Vasc. Biol. 29(6), 950–955 (2009).
   Google Scholar
• Jun M, Foote C, Lv J et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875–1884 (2010).
   Google Scholar
• Ridker PM, Cannon CP, Morrow D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352(1), 20–28 (2005).
   Google Scholar
• LIVALO®, prescribing information. Kowa Pharmaceuticals America Inc., AL, USA (2009).
   Google Scholar
• Kajinami K, Takekoshi N, Saito Y: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.Cardiovasc. Drug Rev. 21(3), 199–215 (2003).
   Google Scholar
• Mukhtar RY, Reid J, Reckless JP: Pitavastatin. Int. J. Clin. Pract. 59(2), 239–252 (2005).
   Google Scholar